Explore News By Topic

03/23/2017

A new approach to target an ‘undruggable’ prostate cancer driver

ANN ARBOR, Michigan — New research suggests a novel strategy to target a genetic anomaly that occurs in half of all prostate cancers. When the genes TMPRSS2 and ERG relocate on a chromosome and fuse together, it’s an on-switch for prostate cancer development. But ERG has proven to be a... Read More

03/02/2017

Study by PCF-Young Investigator identifies how cancer cells may develop resistance to FGFR inhibitors

Columbus, Ohio - A new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor... Read More

02/13/2017

PCF-Funded Research at the Cleveland Clinic Identifies how to Reverse Prostate Cancer Drug Resistance

A Cleveland Clinic research team has uncovered a biological pathway that renders a common prostate cancer drug useless and, for the first time, restored the drug’s cancer-killing power in human prostate cancer tumor cells grown in mice. Results from the study were published online today in the medical journal, eLife.... Read More

12/20/2016

Breast Cancer Research Foundation and Prostate Cancer Foundation Announce Their Commitment to Support the Blood Profiling Atlas in Cancer

In alignment with VP Biden’s Cancer Moonshot initiative, the Blood PAC formed in October 2016 to support progress towards patient benefit through research. Read More

10/24/2016

Genetic Counseling Center Dedicated To Advanced Prostate Cancer Opens In Seattle

Prostate cancer is one of the most heritable forms of cancer. Hereditary mutations in “DNA repair” genes – BRCA1, BRCA2, and others – which are best known for their association with breast and ovarian cancer predisposition, are now known to be associated with advanced prostate cancer. In fact, ~12% of... Read More

07/19/2016

Metastatic Prostate Cancer Cases Skyrocket Increase May Be Due To More Lax Screening Or More Aggressive Disease

Highest increase among men ages 55 to 69, who could benefit the most from screening and early treatment. Disease is more advanced when finally diagnosed. "Screening saves lives," urologists stress. "If I were a patient, I would want to be vigilant." Chicago -- The number of new cases of metastatic... Read More

07/15/2016

New study finds one in nine men with metastatic prostate cancer carry inherited mutations in DNA repair genes with important implications for treatment and for cancer risk in family members

https://www.youtube.com/embed/8pjv5M7G58U Cancer, the uncontrolled growth of cells, is caused by the acquisition of genetic mutations that allow cells to evade the normal biological laws governing when and where they can grow in the body. Mechanisms that maintain the accuracy of our genomes are critical for preventing cells from collecting mutations... Read More

07/07/2016

INHERITED GENETIC MUTATIONS FOUND IN 12% OF MEN WITH METASTATIC PROSTATE CANCER

Mutations in 16 different DNA damage repair (DDR) genes have been identified as drivers of metastatic prostate cancer and other tumors, but are rare in the general population Approximately 12% of men with metastatic prostate cancer harbor inherited (germline) DDR mutations that likely caused their disease, even if they have... Read More

06/24/2016

A NEW GENOMIC CLASSIFIER ENABLES DIAGNOSIS OF THE AGGRESSIVE NEUROENDOCRINE SUBCLASS OF TREATMENT-RESISTANT PROSTATE CANCER

June 24, 2015 -- Tumor cells are continuously evolving to adapt to selective pressures introduced by changing host factors and the administration of new therapies. Following treatment with second-generation anti-androgen therapies abiraterone acetate (Zytiga®) and enzalutamide (Xtandi®), prostate tumors inevitably develop resistance and progress to lethal disease. Anti-androgen therapy-resistant prostate... Read More

06/07/2016

New Clinical Trial Endpoint May Speed The Development Of New Therapies For Patients With Localized Prostate Cancer

At the 2016 American Society of Clinical Oncology (ASCO) Annual Conference, Dr. Christopher Sweeney presented results from ICECaP (Intermediate Clinical Endpoints in Cancer of the Prostate), a Prostate Cancer Foundation (PCF)-supported initiative, that will halve the time required to assess new therapies for aggressive prostate cancer. "We need to move... Read More